331 related articles for article (PubMed ID: 33605827)
1. Recent advances in surgery and its perioperative treatment in people with hemophilia.
Rodríguez-Merchán EC
Expert Rev Hematol; 2021 Mar; 14(3):271-280. PubMed ID: 33605827
[No Abstract] [Full Text] [Related]
2. Hemophilia and von Willebrand's disease: 2. Management. Association of Hemophilia Clinic Directors of Canada.
CMAJ; 1995 Jul; 153(2):147-57. PubMed ID: 7600466
[TBL] [Abstract][Full Text] [Related]
3. Progress in the treatment of bleeding disorders.
Bergman GE
Thromb Res; 2011 Jan; 127 Suppl 1():S3-5. PubMed ID: 21035836
[TBL] [Abstract][Full Text] [Related]
4. Antifibrinolytic therapy for preventing oral bleeding in patients with haemophilia or Von Willebrand disease undergoing minor oral surgery or dental extractions.
van Galen KP; Engelen ET; Mauser-Bunschoten EP; van Es RJ; Schutgens RE
Cochrane Database Syst Rev; 2015 Dec; (12):CD011385. PubMed ID: 26704192
[TBL] [Abstract][Full Text] [Related]
5. Comprehensive care for hemophilia and other inherited bleeding disorders.
Page D
Transfus Apher Sci; 2019 Oct; 58(5):565-568. PubMed ID: 31427262
[TBL] [Abstract][Full Text] [Related]
6. Perioperative continuous infusions of factor VIII versus factor IX for patients with hemophilia A or B undergoing major surgery.
Tse B; Nisenbaum R; Floros G; Jiwajee A; Teitel J; Sholzberg M
J Thromb Thrombolysis; 2023 Feb; 55(2):273-281. PubMed ID: 36547766
[TBL] [Abstract][Full Text] [Related]
7. Management of von Willebrand disease with factor VIII/von Willebrand factor concentrates: results from current studies and surveys.
Federici AB
Blood Coagul Fibrinolysis; 2005 Apr; 16 Suppl 1():S17-21. PubMed ID: 15849522
[TBL] [Abstract][Full Text] [Related]
8. Pioneering designs for recombinant coagulation factors.
Schulte S
Thromb Res; 2011; 128 Suppl 1():S9-12. PubMed ID: 22221848
[TBL] [Abstract][Full Text] [Related]
9. In silico comparison of pharmacokinetic properties of three extended half-life factor IX concentrates.
Preijers T; Bukkems L; van Spengler M; Leebeek F; Cnossen M; Mathôt R
Eur J Clin Pharmacol; 2021 Aug; 77(8):1193-1200. PubMed ID: 33624121
[TBL] [Abstract][Full Text] [Related]
10. Regional variation and cost implications of prescribed extended half-life factor concentrates among U.S. Haemophilia Treatment Centres for patients with moderate and severe haemophilia.
Croteau SE; Cheng D; Cohen AJ; Holmes CE; Malec LM; Silvey M; Thornburg CD; Wheeler AP; Kouides PA; Raffini LJ; Neufeld EJ
Haemophilia; 2019 Jul; 25(4):668-675. PubMed ID: 30993845
[TBL] [Abstract][Full Text] [Related]
11. Efanesoctocog alfa for the prevention and treatment of bleeding in patients with hemophilia A.
Konkle BA
Expert Rev Hematol; 2023; 16(8):567-573. PubMed ID: 37289594
[TBL] [Abstract][Full Text] [Related]
12. Real-World Analysis of Dispensed IUs of Coagulation Factor IX and Resultant Expenditures in Hemophilia B Patients Receiving Standard Half-Life Versus Extended Half-Life Products and Those Switching from Standard Half-Life to Extended Half-Life Products.
Tortella BJ; Alvir J; McDonald M; Spurden D; Fogarty PF; Chhabra A; Pleil AM
J Manag Care Spec Pharm; 2018 Jul; 24(7):643-653. PubMed ID: 29363389
[TBL] [Abstract][Full Text] [Related]
13. Clinical efficacy of highly purified, doubly virus-inactivated factor VIII/von Willebrand factor concentrate (Fanhdi) in the treatment of von Willebrand disease: a retrospective clinical study.
Federici AB; Baudo F; Caracciolo C; Mancuso G; Mazzucconi MG; Musso R; Schinco PC; Targhetta R; Mannuccio Mannucci P
Haemophilia; 2002 Nov; 8(6):761-7. PubMed ID: 12410644
[TBL] [Abstract][Full Text] [Related]
14. No inhibitor development after continuous infusion of factor concentrates in subjects with bleeding disorders undergoing surgery: a prospective study.
Auerswald G; Bade A; Haubold K; Overberg D; Masurat S; Moorthi C
Haemophilia; 2013 May; 19(3):438-44. PubMed ID: 23279056
[TBL] [Abstract][Full Text] [Related]
15. Simplifying surgery in haemophilia B: Low factor IX consumption and infrequent infusions in surgical procedures with rIX-FP.
Curtin J; Santagostino E; Karim FA; Li Y; Seifert W; Négrier C
Thromb Res; 2020 Apr; 188():85-89. PubMed ID: 32109773
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of a new generation von Willebrand factor/factor VIII concentrate (Wilate®) in the management of perioperative haemostasis in von Willebrand disease patients undergoing surgery.
Windyga J; von Depka-Prondzinski M;
Thromb Haemost; 2011 Jun; 105(6):1072-9. PubMed ID: 21437358
[TBL] [Abstract][Full Text] [Related]
17. [Diagnosis and management of coagulation disorders in orthopedic surgery].
Scharrer I
Orthopade; 1999 Apr; 28(4):316-22. PubMed ID: 10335525
[TBL] [Abstract][Full Text] [Related]
18. Analysis of current perioperative management with Haemate
Hazendonk HCAM; Heijdra JM; de Jager NCB; Veerman HC; Boender J; van Moort I; Mathôt RAA; Meijer K; Laros-van Gorkom BAP; Eikenboom J; Fijnvandraat K; Leebeek FWG; Cnossen MH;
Haemophilia; 2018 May; 24(3):460-470. PubMed ID: 29573506
[TBL] [Abstract][Full Text] [Related]
19. Innovative coagulation factors: albumin fusion technology and recombinant single-chain factor VIII.
Schulte S
Thromb Res; 2013 Mar; 131 Suppl 2():S2-6. PubMed ID: 23537723
[TBL] [Abstract][Full Text] [Related]
20. Prevention and Management of Bleeding Episodes in Children with Hemophilia.
Ljung RCR
Paediatr Drugs; 2018 Oct; 20(5):455-464. PubMed ID: 30128815
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
